

- cataract surgery; prospective randomized double-masked clinical trial. *J Cataract Refract Surg* 2007; 33:1925–1929
2. Tetz MR, Nimsger C. Posterior capsule opacification. Part 2: clinical findings. *J Cataract Refract Surg* 1999; 25:1662–1674
  3. Inan ÜÜ, Bozkurt E, Öztürk F, et al. Effect of diclofenac on prevention of posterior capsule opacification in human eyes. *Can J Ophthalmol* 2006; 41:624–629. Available at: <http://pubs.nrc-cnrc.gc.ca/cjo/cjo41/i06-051.pdf>. Accessed December 4, 2007
  4. Inan ÜÜ, Öztürk F, Kaynak S, et al. Prevention of posterior capsule opacification by intraoperative single-dose pharmacologic agents. *J Cataract Refract Surg* 2001; 27:1079–1087

**REPLY:** As stated, the study was double-masked. One ophthalmologist performed the surgery, and 1 ophthalmologist conducted the postoperative evaluation. Neither ophthalmologist was aware of which NSAIDs the patients were instilling. During the study period, the ophthalmic technicians were responsible for ensuring that patients were using the appropriate medications along with proper dosing in the absence of the ophthalmologist; ie, during the history portion of the visit. Before, during, or after the ophthalmic examination, the ophthalmic technician would verbally relay to the ophthalmologist that the patient was instilling the appropriate topical medication with the correct dosing without verbalizing the actual dosing regimen. The evaluating ophthalmologist was instructed not to ask the patient what topical medications he or she was using. The electronic medical record documented the postoperative pharmacological drug class without referencing the name of the NSAID, steroid, antimicrobial, and the dosing regimen. I believe the process used for this study does minimize, if not eliminate, true or potential biases from the examining ophthalmologist even if the dosing frequencies of the medications differ.

Apart from the patients being cleared for cataract surgery, the surgical counselor did not know the patients' medical and ocular histories. When the patient consented to be enrolled in the study, the respective topical medication was given at random; it was not based on financial or social factors, insurance, or demographics. Owing to the frequency with which cataract surgery patients change their minds, become ill, or experience unexpected life-altering events, random distribution was determined to be best. It is valid to question the practice of switching the colored labeling of the masked groups each month; however, a built-in method to prevent mixing the groups was used. In the surgery log generated by the surgery counselor, the respective NSAIDs were recorded along with the color code for the month. The discharging nurse had a list of patients along with the surgery log and next to the patient's name was the appropriate postoperative kit to be given. The red or blue label was used to group

the patients so that during the data collection period, the number of patients and the names of patients were correctly matched and recorded.

Posterior capsule opacification is an inherent postoperative complication in cataract surgery. Research, intraocular lens design, surgical techniques, and pharmacotherapy have significantly decreased the incidence of PCO. In this study, the incidence of PCO was high; however, it was clearly stated in the article that the "true" prevalence of PCO could not be determined and further evaluation was needed at 6 and 12 months to assess whether there was a direct correlation between the use of nepafenac and the development of early PCO. In the article, all the points (ie, preoperatively, intraoperatively) potentially associated with the development of PCO were made. In short, what was observed was reported but there was latitude in terms of correlation.

All the study patients were instructed to use their respective medications 3 days before surgery. Before discharge and in addition to the topical steroid, the patients were instructed to continue using their respective preoperative medications until further instructions were given. Along with other indications, both medications were indicated for ocular pain management postoperatively. The survey was given to address pain control in the immediate postoperative period and within the first 48 hours. I agree that in general, surveys are subjective, but I disagree with the comment that we "overstate the importance of the difference . . ." The subjective nature of the survey was quantified, and the important differences were not overstated. The study simply reported the numeric value. In my opinion, the language used to report the finding was succinct. It was suggested that a more appropriate conclusion would be, "Nepafenac 3 times a day and ketorolac 4 times a day were both effective and clinically comparable in anterior segment ophthalmic surgery and patient perception." The first part of the statement is true and was clearly stated in the first line of the last paragraph in the discussion. The second part, "patient perception," is incorrect. If that statement were made, it would surely contradict the statistical findings.

Finally, the study was conducted at a single-center private practice and no party involved had any financial or proprietary gains. The study was not funded by a company or institution. It was conducted to assess overall patient satisfaction with the respective NSAIDs and potential clinical outcomes. Outcomes from studies will be positive or negative and in the purest definition of the scientific method, this study was conducted ethically and without bias or incentive.—*Hon-Vu Quang Duong, MD, Kenneth C. Westfield, MD, Thomas H. Chalkley, MD*